Abstract: A separation device receives a known or unknown glycan that is co-injected with three different oligomers maltooligosaccharide (MOL). A detector measures the separated glycan and the separated three different oligomers as intensity peaks that are a function of migration time. The migration times of a plurality of other oligomers of MOL are calculated from the migration times of the three different oligomers. Glucose unit (GU) values for the intensity peaks of the separated glycan are calculated by comparing their migration times to the calculated migration times of the plurality of other oligomers of MOL. The processor identifies the structure of the glycan by comparing the calculated GU values of the intensity peaks of the separated glycan to a database of GU values for known glycan structures.

Abstract: Flow capture device and method for removing cells from blood The current invention discloses a blood treating and/or purifying device for removing circulating pathogens, preferably pathogenic cells, more preferably circulating tumor cells from the blood of a patient, a method of producing such a device and method to treat cancer and other diseases caused by virus infection, bacterial infection and parasites infection as well as autoimmune disorders. The described method is an extracorporeal medical therapy, thus can be done also in a hemodialysis system. The current invention also describes a device and an in-situ production method of preparing the device to remove CTC and other pathogens i.e. virus, bacteria or parasites from the bloodstream.

Abstract: A sample preparation workflow to facilitate deep N-glycomics analysis of human serum by capillary electrophoresis with laser induced fluorescence (CE-LIF) detection accommodates the higher sample concentration requirement of electrospray ionization mass spectrometry connected to capillary electrophoresis (CE-ESI-MS). A temperature gradient denaturing protocol is applied on amine functionalized magnetic bead partitioned glycoproteins to avoid precipitation. This also results in the free sugar content of the serum being significantly decreased which allows PNGase F mediated release of the N-linked carbohydrates. The liberated oligosaccharides were tagged with aminopyrene-trisulfonate, utilizing a modified evaporative labeling protocol. This workflow provides appropriate amounts of material for example for use in CE-ESI-MS analysis in negative ionization mode.

Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method using magnetic beads containing negatively charged carboxyl groups extending from the surface of the magnetic beads.

Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method using magnetic beads containing negatively charged carboxyl groups extending from the surface of the magnetic beads.

Abstract: A holder that can be used to stand up a PCR tube on a flat surface or held in a user's hand. The holder has a first elongated portion, a second elongated portion and a third elongated portion. The first elongated portion having a magnet, the second elongated portion having a tube holding means and the third elongate portion acting as a stabilizer to allow the holder to standup in an upright position. The third elongate portion can also be used as a gripping surface to be held between fingers of a hand.

Abstract: Flow capture device and method for removing cells from blood The current invention discloses a blood treating and/or purifying device for removing circulating pathogens, preferably pathogenic cells, more preferably circulating tumor cells from the blood of a patient, a method of producing such a device and method to treat cancer and other diseases caused by virus infection, bacterial infection and parasites infection as well as autoimmune disorders. The described method is an extracorporeal medical therapy, thus can be done also in a hemodialysis system. The current invention also describes a device and an in-situ production method of preparing the device to remove CTC and other pathogens i.e. virus, bacteria or parasites from the bloodstream.

Abstract: Fluorescently labeled molecules of a sample are quantitated in an ion source device of a mass spectrometer. An illumination source device to illuminates at least a first portion of a sample. The sample is illuminated to excite fluorescently labeled molecules of the sample as it is being ionized in the ion source device. A two-dimensional digital image detector measures an image of at least a second portion of the illuminated first portion of the sample at each time interval of a plurality of time intervals. Each measured image at each of the plurality of time intervals is stored in a memory device. A trace of the intensity of the second portion as a function of time is calculated from the stored measured images. A quantity of the fluorescently labeled molecules is calculated from the trace of the calculated intensity of the second portion as a function of time.

Abstract: A holder that can be used to stand up a PCR tube on a flat surface or held in a user's hand. The holder has a first elongated portion, a second elongated portion and a third elongated portion. The first elongated portion having a magnet, the second elongated portion having a tube holding means and the third elongate portion acting as a stabilizer to allow the holder to standup in an upright position. The third elongate portion can also be used as a gripping surface to be held between fingers of a hand.

Abstract: A separation device receives a known or unknown glycan that is co-injected with three different oligomers maltooligosaccharide (MOL). A detector measures the separated glycan and the separated three different oligomers as intensity peaks that are a function of migration time. The migration times of a plurality of other oligomers of MOL are calculated from the migration times of the three different oligomers. Glucose unit (GU) values for the intensity peaks of the separated glycan are calculated by comparing their migration times to the calculated migration times of the plurality of other oligomers of MOL. The processor identifies the structure of the glycan by comparing the calculated GU values of the intensity peaks of the separated glycan to a database of GU values for known glycan structures.

Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol that can enable full automation and reduced sample preparation time relative to current methods of glycoanalysis. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method without requiring time-consuming sample preparation steps such as centrifugation or vacuum-centrifugation.

Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol that can enable full automation and reduced sample preparation time relative to current methods of glycoanalysis. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method without requiring time-consuming sample preparation steps such as centrifugation or vacuum-centrifugation.

Abstract: N-glycosylation profiling of glycoprotein biotherapeutics is an essential step in each phase of product development in the biopharmaceutical industry. For example, during clone selection hundreds of clones should be analyzed quickly from limited amounts of samples. On the other hand, identification of disease related glycosylation alterations can serve as early indicators for various pathological conditions in the biomedical field. We describe an improved packed bed column PNGase F functionalized column reactor. The reactor may be packed into a pipette tip column. In some embodiments, a second column or mixed stationary phase may be packed into the column to capture and purify the cleaved glycan prior to analysis. Complete N-glycan removal can be obtained in 10 minutes from all major N-linked glycoprotein types. The approach can be readily applied to automated sample preparation systems, such as liquid handling robots.

Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol that can enable full automation and reduced sample preparation time relative to current methods of glycoanalysis. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method without requiring time-consuming sample preparation steps such as centrifugation or vacuum-centrifugation.

Abstract: A method or platform for monoclonal antibody based biomarker discovery is disclosed. The method according to the invention provides for the integration of analyte collection, hybridoma screening and nanovolume integrated mass spectrometry (NVIMS) to achieve a robust screening system that is capable, for example, of cutting 4-6 years off of the classical biomarker discovery and development process. The invention provides a platform for the rapid, high-throughput production, isolation and characterization of, e.g., disease specific biomarkers together with highly specific monoclonal antibodies. The method of the invention has a variety of applications such as, but not limited to, drug testing, biohazard applications, ecological applications, physiological applications and/or pathology screening applications. The method of the invention is also capable of being performed or used as or with a high-throughput screening process or system of the invention.

Abstract: A cost-effective multi-channel capillary gel-electrophoresis system for highly efficient, high speed, high throughput, carbohydrate analysis. In one aspect of the present invention, a high-performance capillary electrophoresis analyzer system has been optimized for carbohydrate analysis application. The system uses a multiplexed/time-staggered fluorescence type detection mechanism, with an integrated fiber optic array-based technology and a novel disposable gel-cartridge. Twelve carbohydrate samples are automatically injected, electrophoretically separated, detected and analyzed simultaneously by using a multiple usage and disposable multi-capillary gel-cartridge. Using commercially available labeling agent such as APTS (representing 8-Aminopyrene-1,3,6-trisulfonic acid, trisodium salt) as an indicator, the capillary electrophoresis-based carbohydrate system/analyzer provides high resolving power in 2-15 minutes of separations.

Abstract: The present invention relates to an efficient mAb panel-based expression profiling technology platform suitable for global and accurate measurement of proteins, peptides and metabolites in complex mixtures. The platform is comprised of new and well established technologies that are coupled in a unique fashion to provide a novel platform technology for (i) the discovery of differentially displayed elements of complex protein, peptide and metabolite mixtures and (ii) the development of robust mAb based assays that detect the differentially expressed elements.

Abstract: Reactors and methods for miniaturized reactions having enhanced reaction kinetics. In particular the subject matter is directed to chemical and biological reactions conducted in a nanoporous membrane environment. The subject matter contemplates methods for modifying the kinetics of reactions and devices for conducting reactions having modified kinetics. The subject matter also provides systems for rapid miniaturized reactions. Further the subject matter includes methods and kits for conducting a reaction with enhanced throughput and methods of conducting miniaturized, high throughput analyses of reaction products, and the like. Reactions performed on or within a nanoporous membrane exhibits improved kinetic characteristics.

Abstract: The present invention relates to methods for identifying antigens from complex analyte samples. More specifically, the invention relates to methods for identifying antigens recognized by monoclonal antibodies in a complex analyte sample. The methods of this invention use a first affinity chromatography via a “multiaffinity” step and a second, “singleaffinity” step that implements parallel affinity chromatography.

Abstract: The present invention relates to methods and compositions for the normalization of complex analyte mixtures. The invention allows the preparation of profiled samples from highly complex analyte mixtures, allowing the identification of relevant targets or biomarkers. The invention also relates to methods for producing devices, such as a support, suitable for normalization of complex analyte samples. The invention can be used for the normalization of any complex mixture, such as immunogenic libraries, particularly of human source, and to identify or produce biomarkers highly relevant to human traits or conditions.